<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJBM</journal-id><journal-title-group><journal-title>Open Journal of Business and Management</journal-title></journal-title-group><issn pub-type="epub">2329-3284</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojbm.2024.121019</article-id><article-id pub-id-type="publisher-id">OJBM-130690</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Business&amp;Economics</subject></subj-group></article-categories><title-group><article-title>
 
 
  Visualizing Income Statements of Pharmaceutical Companies Using Sankey Diagrams
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Niah</surname><given-names>Goudar</given-names></name><xref ref-type="aff" rid="aff1"><sub>1</sub></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>College of Engineering and Haas School of Business, University of California, Berkeley, USA</addr-line></aff><pub-date pub-type="epub"><day>06</day><month>12</month><year>2023</year></pub-date><volume>12</volume><issue>01</issue><fpage>266</fpage><lpage>274</lpage><history><date date-type="received"><day>31,</day>	<month>October</month>	<year>2023</year></date><date date-type="rev-recd"><day>21,</day>	<month>January</month>	<year>2024</year>	</date><date date-type="accepted"><day>24,</day>	<month>January</month>	<year>2024</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Financial statement analysis is foundational to evaluate business performance and the income statement provides key insights into the profitability of an enterprise. While income statement data are readily available as part of a company’s annual 10-K filing, their tabular format can make it challenging to fully understand the nuances associated with company performance. To address this shortcoming, the SankeyArt platform was used to develop Sankey diagrams for 3 pharmaceutical companies that provide an alternate intuitive visual representation of company profitability. The level of income statement granularity can be modulated in the Sankey diagrams
  ,
   directing focus to the areas of interest. The approach described in this study is generic and applicable across industries.
 
</p></abstract><kwd-group><kwd>Biotechnology</kwd><kwd> Financial Statement</kwd><kwd> Income Statement</kwd><kwd> Pharmaceuticals</kwd><kwd> Sankey Diagram</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Financial statement analysis is foundational to understating the performance of a company across multiple dimensions  (Fridson &amp; Alvarez, 2022) . In the United States, publicly traded companies are regulated by the Securities and Exchange Commission (SEC). Additionally, the Financial Accounting Standards Board (FASB) sets financial and reporting standards, including generally accepted accounting principles (GAAP), and publicly traded companies in the US are required to follow GAAP. Under GAAP, companies are required to create a balance sheet, a cash flow statement, and an income statement which collectively form the basis of financial statement analysis  (Konchitchki &amp; Patatoukas, 2014) .</p><p>The income statement is most helpful to analyze the profit and loss associated with a business  (Wahlen &amp; Wieland, 2011) . It starts with total revenues, and subtraction of direct costs associated with revenue generation helps identify the gross income and the associated gross margin. Subsequently, indirect expenses like research and development (R&amp;D), marketing, and other costs are subtracted leading up to the operating income and the associated operating margin. Finally, interest and income tax expenses are subtracted from the operating income resulting in the net income and the associated net margin. The net income is a key indicator of profitability, and the net margin enables comparison of company performance against industry peers  (Flood, 2022) .</p></sec><sec id="s2"><title>2. Literature Review</title><p>Income statements are shared both quarterly and annually and are key component of a corporation’s financial statement analysis  (Monahan, 2018) . They contain all the information necessary to determine a company’s profitability and their presentation in a tabular form is the accepted practice across the globe  (Hasanaj &amp; Kuqi, 2019) . However, it has been shown that the format in which information is presented can affect the judgement of the reader of the financial statement  (Liang &amp; Zhang, 2006) . For instance, investors were prone to misjudgment when information was disclosed as a footnote or in other less prominent formats  (Maines &amp; McDaniel, 2000) . Providing a search option via eXtensible Business Reporting Language (XRBL) to access financial statement and footnote information increased the likelihood of users obtaining information on stock option compensation that was disclosed in the footnotes which impacted their investment decisions  (Hodge, Kennedy, &amp; Maines, 2004) . A subsequent study  (Nelson &amp; Tayler, 2007)  showed that data transformation by the user could impact their judgement, highlighting the importance of clarity in the presentation of financial statement data.</p><p>Furthermore, financial statement review and interpretation is not constrained to subject matter experts. Company financial statements are read by a diverse audience with varying levels of expertise  (Cascino et al., 2014) , and simplification of the presentation should translate to consistent understanding of company performance across all stakeholders. We believe an alternate visual representation could provide useful insights into company performance and simplify interpretation of income statements, which is the basic premise of this article.</p><p>One such visualization is the Sankey diagram, originally proposed to describe the efficiency of steam engines  (Kennedy &amp; Sankey, 1898)  and since been applied across disciplines including material flows  (Graedel, 2019) , energy flows  (Schmidt, 2008;   Subramanyam et al., 2015) , water resource management  (Curmi et al., 2013) , financial analysis  (Ioannidou et al., 2018;   Chong et al., 2021) , visualizing microbial communities  (Platzer et al., 2018) , and the teaching of economics  (de-C&#243;rdoba &amp; Molinari, 2022) , to name a few applications. Because Sankey diagrams provide excellent visual interpretation of complex data, the underlying relationships that define the data are easier to understand and compare across scenarios.</p></sec><sec id="s3"><title>3. Objective of This Study</title><p>To simplify the interpretation of income statements, we have developed Sankey diagrams for 3 pharmaceutical companies. This article includes a Materials and Methods section that lists the companies chosen for analysis along with the approach used to create Sankey diagrams for their income statements. The results section presents Sankey diagrams for the 3 companies along with an interpretation of the income statements. Finally, the conclusions section provides a holistic view of how Sankey diagrams simplify income statement analysis and their broad applicability across industries. These visual representations simplify profitability analysis enabling intuitive and rapid understanding of profit and loss. The approach presented in this study is general and applicable across industries.</p></sec><sec id="s4"><title>4. Materials and Methods</title><sec id="s4_1"><title>4.1. Choice of Companies for Analysis</title><p>A total of 3 pharmaceutical companies (AbbVie, Merck and Co., and Amgen) were used in this analysis and their choice was driven primarily by the desire to include income statement diversity that would manifest in the Sankey visualizations. Abbvie did not break down 2022 revenues by categories or products and total revenues were consolidated into a single number. In contrast, Merck and Co. reported revenues across therapeutic areas and product categories resulting in more granularity compared to Abbvie and a more informative Sankey diagram. Amgen was selected because it provided the highest granularity by including revenues across each of its products. Consequently, Amgen had the highest resolution revenue breakdown resulting in the most information-rich Sankey diagram. These 3 companies represent the full spectrum of granularity expected in income statements and their associated Sankey diagrams showcase the range of income statement visualizations. For each of the 3 companies, 2022 annual income statement data were obtained from their 10-K filings (sec.gov/ edgar).</p></sec><sec id="s4_2"><title>4.2. Construction of Sankey Diagrams</title><p>The web based SankeyArt platform (https://www.sankeyart.com/) was used to construct the Sankey diagrams presented in this study. SankeyArt is intuitive and user friendly with a spreadsheet like interface to enter income statement data followed by multiple options to customize the appearance of the final Sankey diagram. As an illustration, the data entry interface for the company Merck &amp; Co. is shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></sec></sec><sec id="s5"><title>5. Results</title><p>Income statements across 3 pharmaceutical companies were used to generate their corresponding Sankey diagrams. Differences in how the revenue contributions were described result in changes to the Sankey diagrams as will be shown in corresponding sections.</p><sec id="s5_1"><title>5.1. AbbVie</title><p>AbbVie’s consolidated statement of earnings starts with total revenues of $58.05B which form the first node in the Sankey Diagram (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Subsequently, expenses across 5 categories, cost of sales (COS), selling general &amp; administrative (SG&amp;A), research &amp; development (R&amp;D), acquired IPR&amp;D and milestones, and operating expenses, are depicted as outflows resulting in an operating income of $18.12B, the second node in <xref ref-type="fig" rid="fig2">Figure 2</xref>. From the operating income node, foreign exchange loss, interest, and other expenses are outflows leading to the income before taxes node of $13.48B. Finally, subtracting the income tax expense of $1.63B leads to the net income of $11.85B.</p><p>A simple color scheme (grey = neutral, red = expense, green = profit) makes the visualization intuitive and because the thickness of the lines is proportional to the magnitude of the value, relative contributions stand out. For instance, the</p><p>much higher cost of sales and selling general &amp; administrative expenses compared to research &amp; development investments (2.3 - 2.6X, respectively) are visually obvious from <xref ref-type="fig" rid="fig2">Figure 2</xref>. Similarly, a relatively modest outflow as income tax expense ($1.63B) from the income before taxes node ($13.48B) is also evident from <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p></sec><sec id="s5_2"><title>5.2. Merck and Co</title><p>Merck reported 2022 revenues across its pharmaceutical ($52.01B), animal health ($5.55B), and other ($1.73B) segments leading up to total revenues of $59.28B (<xref ref-type="fig" rid="fig3">Figure 3</xref>). The dominant contribution from the pharmaceutical segment is evident in <xref ref-type="fig" rid="fig3">Figure 3</xref>. Furthermore, each revenue segment was further broken down across therapeutic areas and other categories and a higher resolution view into the contributors of revenue is seen in <xref ref-type="fig" rid="fig3">Figure 3</xref>. Oncology, vaccines, and virology make up the top 3 contributors with the combined animal health segment coming in at 4<sup>th</sup> place.</p><p>Merck’s R&amp;D expense ($13.55B) was greater than their SG&amp;A expense ($10.04B)</p><p>and slightly lower than their cost of goods sold ($17.41B). This is in stark contrast to AbbVie (<xref ref-type="fig" rid="fig2">Figure 2</xref>) where the SG&amp;A and COS were &gt; 2-fold higher than the R&amp;D expense. Finally, income tax and other expense outflows from the operating income ($16.44B) result in a net income of $14.52B at a income tax rate of ~12%, similar to that for AbbVie in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p><p>In contrast to <xref ref-type="fig" rid="fig2">Figure 2</xref> where the first node was total revenues, <xref ref-type="fig" rid="fig3">Figure 3</xref> is a more granular depiction of the contributors to Merck’s revenues. Their relative contributions can be easily visualized by the thickness of the connectors and arranging them in descending order also helps contextualize their overall position.</p></sec><sec id="s5_3"><title>5.3. Amgen</title><p>Amgen reported revenue at the product level where 23 products were individually called out along with an Other Products category. Collectively, these resulted in $24.8B of product-associated revenue and comprise the first node on the Amgen Sankey diagram (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Other revenues were $1.52B resulting in the total revenue node of $26.32B. <xref ref-type="fig" rid="fig4">Figure 4</xref> includes a gross profit node (this was not shown in <xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3</xref>) to illustrate that variations of the Sankey diagram can be generated depending upon the focus and intent of the analysis.</p><p>Accounting for R&amp;D, SG&amp;A, and other Opex outflows from the gross profit node leads to the operating income node. Similar to <xref ref-type="fig" rid="fig2">Figure 2</xref>, a pre-tax income node after accounting for interest and other expenses is included in <xref ref-type="fig" rid="fig4">Figure 4</xref> which ultimately leads to net income after accounting for the income tax outflow.</p><p>If required, Amgen products can be grouped by therapeutic area resulting in additional nodes prior to the products node. This would enable direct comparison of contributions across the therapeutic areas, something that is not easy to determine from <xref ref-type="fig" rid="fig4">Figure 4</xref>.</p></sec></sec><sec id="s6"><title>6. Conclusion</title><p>Using Sankey diagrams, we have developed intuitive visual representations for the income statements of AbbVie, Merck and Co., and Amgen, three pharmaceutical companies. These diagrams are intuitive and easy to follow, enabling rapid insights into company performance. Depending on the end user, these diagrams can be customized, and the granularity can be adjusted to provide specific insights for decision making.</p><p>We recommend financial analysts use Sankey diagrams in addition to conventional tabulated income statements to analyze company performance and include them in their company reports. This will simplify interpretation of company performance across a broad range of consumers, especially those without formal training in finance.</p><p>Sankey diagrams are relatively easy to construct, and their general nature makes them applicable across the spectrum of publicly traded companies across the globe. We believe they are the method of choice for intuitive and visual interpretation of income statements and need broader adoption to maximize their impact.</p></sec><sec id="s7"><title>Acknowledgements</title><p>I thank Andy Haselsteiner, creator of the SankeyArt.com platform that was used to generate the Sankey diagrams presented in this study.</p></sec><sec id="s8"><title>Conflicts of Interest</title><p>The author declares no conflict of interest regarding the publication of this paper.</p></sec><sec id="s9"><title>Cite this paper</title><p>Goudar, N. (2024). Visualizing Income Statements of Pharmaceutical Companies Using Sankey Diagrams. Open Journal of Business and Management, 12, 266-274. https://doi.org/10.4236/ojbm.2024.121019</p></sec></body><back><ref-list><title>References</title><ref id="scirp.130690-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Cascino, S., Clatworthy, M., Osma, B. G., Gassen, J., Imam, S., &amp; Jeanjean, T. (2014). Who Uses Financial Reports and for What Purpose? Evidence from Capital Providers. Accounting in Europe, 11, 185-209. https://doi.org/10.1080/17449480.2014.940355</mixed-citation></ref><ref id="scirp.130690-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Schmidt, M. (2008). The Sankey Diagram in Energy and Material Flow Management. Journal of Industrial Ecology, 12, 82-94. https://doi.org/10.1111/j.1530-9290.2008.00004.x</mixed-citation></ref><ref id="scirp.130690-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Subramanyam, V., Paramshivan, D., Kumar, A., &amp; Mondal, Md. A. H. (2015). Using Sankey Diagrams to Map Energy Flow from Primary Fuel to End Use. Energy Conversion and Management, 91, 342-352. https://doi.org/10.1016/j.enconman.2014.12.024</mixed-citation></ref><ref id="scirp.130690-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Wahlen, J. M., &amp; Wieland, M. M. (2011). Can Financial Statement Analysis Beat Consensus Analysts’ Recommendations? Review of Accounting Studies, 16, 89-115. https://doi.org/10.1007/s11142-010-9124-5</mixed-citation></ref><ref id="scirp.130690-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Platzer, A., Polzin, J., Rembart, K., Han, P. P., Rauer, D., &amp; Nussbaumer, T. (2018). BioSankey: Visualization of Microbial Communities over Time. Journal of Integrative Bioinformatics, 15, Article 20170063. https://doi.org/10.1515/jib-2017-0063</mixed-citation></ref><ref id="scirp.130690-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Nelson, M. W., &amp; Tayler, W. B. (2007). Information Pursuit in Financial Statement Analysis: Effects of Choice, Effort, and Reconciliation. The Accounting Review, 82, 731-758. https://doi.org/10.2308/accr.2007.82.3.731</mixed-citation></ref><ref id="scirp.130690-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Monahan, S. J. (2018). Financial Statement Analysis and Earnings Forecasting. Foundations and Trends&amp;#174; in Accounting, 12, 105-215. https://doi.org/10.1561/1400000036</mixed-citation></ref><ref id="scirp.130690-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Maines, L. A., &amp; McDaniel, L. S. (2000). Effects of Comprehensive-Income Characteristics on Nonprofessional Investors’ Judgments: The Role of Financial-Statement Presentation Format. The Accounting Review, 75, 179-207. https://doi.org/10.2308/accr.2000.75.2.179</mixed-citation></ref><ref id="scirp.130690-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Liang, P. J., &amp; Zhang, X.-J. (2006). Accounting Treatment of Inherent versus Incentive Uncertainties and the Capital Structure of the Firm. Journal of Accounting Research, 44, 145-176. https://doi.org/10.1111/j.1475-679X.2006.00195.x</mixed-citation></ref><ref id="scirp.130690-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Konchitchki, Y., &amp; Patatoukas, P. N. (2014). Taking the Pulse of the Real Economy Using Financial Statement Analysis: Implications for Macro Forecasting and Stock Valuation. The Accounting Review, 89, 669-694. https://doi.org/10.2308/accr-50632</mixed-citation></ref><ref id="scirp.130690-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kennedy, A. B. W., &amp; Sankey, H. R. (1898). The Thermal Efficiency of Steam Engines. Report of the Committee Appointed to the Council upon the Subject of the Definition of a Standard or Standards of Thermal Efficiency for Steam Engines: With an Introductory Note (Including Appendixes and Plate at Back of Volume). Minutes of the Proceedings of the Institution of Civil Engineers, 134, 278-312. https://doi.org/10.1680/imotp.1898.19100</mixed-citation></ref><ref id="scirp.130690-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ioannidou, D., Zerbi, S., de Soto, B. G., &amp; Habert, G. (2018). Where Does the Money Go? Economic Flow Analysis of Construction Projects. Building Research &amp; Information, 46, 348-366. https://doi.org/10.1080/09613218.2017.1294419</mixed-citation></ref><ref id="scirp.130690-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Hodge, F. D., Kennedy, J. J., &amp; Maines, L. A. (2004). Does Search-Facilitating Technology Improve the Transparency of Financial Reporting? The Accounting Review, 79, 687-703. https://doi.org/10.2308/accr.2004.79.3.687</mixed-citation></ref><ref id="scirp.130690-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Hasanaj, P., &amp; Kuqi, B. (2019). Analysis of Financial Statements. Humanities and Social Science Research, 2, 17-27. https://doi.org/10.30560/hssr.v2n2p17</mixed-citation></ref><ref id="scirp.130690-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Graedel, T. E. (2019). Material Flow Analysis from Origin to Evolution. Environmental Science &amp; Technology, 53, 12188-12196. https://doi.org/10.1021/acs.est.9b03413</mixed-citation></ref><ref id="scirp.130690-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Fridson, M. S., &amp; Alvarez, F. (2022). Financial Statement Analysis, 5th Edition: A Practitioner’s Guide (5th ed.). Wiley. https://doi.org/10.1002/9781119457176</mixed-citation></ref><ref id="scirp.130690-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Flood, J. M. (2022). Wiley GAAP 2023: Interpretation and Application of Generally Accepted Accounting Principles (1st ed.). Wiley. https://doi.org/10.1002/9781119736202</mixed-citation></ref><ref id="scirp.130690-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">de-Córdoba, G. F., &amp; Molinari, B. (2022). Sankey Diagrams for Macroeconomics: A Teaching Complement Bridging Undergraduate and Graduate Macro. Heliyon, 8, E10717. https://doi.org/10.1016/j.heliyon.2022.e10717</mixed-citation></ref><ref id="scirp.130690-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Curmi, E., Fenner, R., Richards, K., Allwood, J. M., Bajzelj, B., &amp; Kopec, G. M. (2013). Visualising a Stochastic Model of Californian Water Resources Using Sankey Diagrams. Water Resources Management, 27, 3035-3050. https://doi.org/10.1007/s11269-013-0331-2</mixed-citation></ref><ref id="scirp.130690-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Chong, C., Zhang, X., Kong, G., Ma, L., Li, Z., Ni, W., &amp; Yu, E.-H.-C. (2021). A Visualization Method of the Economic Input-Output Table: Mapping Monetary Flows in the Form of Sankey Diagrams. Sustainability, 13, Article 12239. https://doi.org/10.3390/su132112239</mixed-citation></ref></ref-list></back></article>